Jan 27 (Reuters) - Alexandria Real Estate Equities ARE.N posted a rise in its fourth-quarter funds from operations on Monday, as the real estate investment trust benefited from steady leasing demand from biotech clients and technology-focused firms.
The Pasadena, California-based company operates and develops life science laboratories, offices and technology campuses across North America.
Its clients include Bristol Myers Squibb BMY.N, Moderna MRNA.O and Eli Lilly LLY.N, as well as agricultural tech companies and research institutions.
Occupancy of Alexandria's operating properties held steady at 94.6% as of Dec. 31, compared with the year earlier.
FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago.
Its total revenue for the quarter rose 4.2% to $788.9 million.
(Reporting by Aatreyee Dasgupta and Nathan Gomes in Bengaluru; Editing by Shilpi Majumdar)
((Aatreyee.Dasgupta@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。